These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 7049376

  • 1. Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
    Holland JF, Ohnuma T.
    Cancer Treat Rep; 1981; 65 Suppl 4():123-30. PubMed ID: 7049376
    [Abstract] [Full Text] [Related]

  • 2. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.
    Ortega JA, Nesbit ME, Donaldson MH, Hittle RE, Weiner J, Karon M, Hammond D.
    Cancer Res; 1977 Feb; 37(2):535-40. PubMed ID: 264412
    [Abstract] [Full Text] [Related]

  • 3. [Letter: Acute lymphoid leukemia: constant induction of remission by the combination of prednisone, vincristine and L-asparaginase (20 cases)].
    Mathe G, Pouillart P, De Vassal F, Delgado M, Schwarzenberg L, Misset JL, Hayat M, Jasmin C, Belpomme D, Musset M.
    Nouv Presse Med; 1976 Jun 05; 5(23):1491. PubMed ID: 1064849
    [No Abstract] [Full Text] [Related]

  • 4. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep 05; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Preliminary results of the clinical study of a Soviet--produced L-asparaginase from E. coli].
    Kondrat'eva NA, Lorie IlI, Kruglova GV, Vorob'ev AI, Koshel' IV.
    Antibiotiki; 1977 Sep 05; 22(9):852-7. PubMed ID: 334060
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Asparaginase: molecular and enzymic requirements for use as an antileukaemia agent.
    Wade HE.
    J Gen Microbiol; 1971 Mar 05; 65(3):x-xi. PubMed ID: 4997395
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Optimal current treatment of childhood acute lymphoblastic leukemia.
    Simone JV.
    Cancer Treat Rep; 1981 Mar 05; 65 Suppl 4():97-100. PubMed ID: 7049384
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vincristine and prednisone vs vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children.
    Herson J, Starling KA, Dyment PG, Humphrey GB, Pullen J, Vats T.
    Med Pediatr Oncol; 1979 Mar 05; 6(4):317-23. PubMed ID: 384187
    [Abstract] [Full Text] [Related]

  • 18. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
    Nath CE, Dallapozza L, Eslick AE, Misra A, Carr D, Earl JW.
    Biomed Chromatogr; 2009 Feb 05; 23(2):152-9. PubMed ID: 18823071
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.